Recent Updates
Recently added Catalysts
BIOA Negative Sentiment Score: 25/100

BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating BioAge Labs, Inc. for potential fiduciary breaches following a class action complaint related to the company's IPO. This investigation comes after BioAge announced the discontinuation of its STRIDES Phase 2 trial for azelaprag, its lead candidate, due to safety concerns. The announcement led to a significant decline in the company's stock price, highlighting the impact of the trial's discontinuation on investor confidence.

Market Sentiment Analysis

CONCERNS & RISKS

  • BioAge Labs faces a class action complaint regarding potential fiduciary breaches.
  • The discontinuation of the STRIDES Phase 2 trial for azelaprag raises safety concerns.
  • The company's stock price plummeted from $20.09 to $4.65 following negative news.

Full Press Release Details

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA) on behalf of long-term stockholders following a class action complaint that was filed against BioAge on January 7, 2024 with a Class Period pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024. Our investigation concerns whether the board of directors of BioAge have breached their fiduciary duties to the company.
According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs.
Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.
If you are a long-term stockholder of BioAge, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the investigation about BioAge Labs?

Bragar Eagel & Squire is investigating potential claims against BioAge Labs' board regarding fiduciary breaches following a class action complaint.

Why was BioAge's STRIDES Phase 2 trial discontinued?

The STRIDES Phase 2 trial for azelaprag was halted due to safety concerns related to elevated liver transaminase levels in participants.

How did BioAge's stock react to the trial news?

BioAge's stock price dropped significantly from $20.09 on December 6, 2024, to $4.65 the next day.

Who can contact Bragar Eagel & Squire for more information?

Long-term stockholders of BioAge who have information or questions can reach out to the firm at investigations@bespc.com.

Where is Bragar Eagel & Squire located?

Bragar Eagel & Squire has offices in New York, South Carolina, and California.

Last updated: Oct 2, 2025